On March 27, 2020, the President signed the Coronavirus Aid, Relief, and Economic Security (CARES) Act.
Following the passage of the LAB Act, CMS issued a transmittal that specifies the new data reporting period for CDLTs that are not ADLTs.
On December 19, Congress passed the Laboratory Access for Beneficiaries (LAB) Act as part of an end-of-year spending package signed into law by the President on December 20.
CMS has published its application for new “U” codes for advanced diagnostic laboratory tests (ADLTs) and FDA-cleared or approved clinical diagnostic laboratory tests (CDLTs).
Here is the link to the inquiry.
CMS has released a new set of frequently asked questions addressing lab data collection.
Diagnostics: Payment Rates
CMS has released the final CY 2019 payment rates for clinical diagnostic services along with supporting instructional materials.
OIG releases the fourth in a series of data briefs looking at Medicare spending under the Clinical Laboratory Fee Schedule.
On Monday December 11, the American Clinical Laboratory Association (ACLA) filed a legal challenge to CMS’s implementation of the revised Clinical Laboratory Fee Schedule (CLFS) required under Section 216 of the Protecting Access to Medicare Act (PAMA) of 2014.
CMS discusses their proposed laboratory test packaging policy on page 45,628
The Centers for Medicare and Medicaid Services today posted the long-awaited proposed rule to implement section 216 of the Protecting Access to Medicare Act.